Putting cardiovascular risk into perspective: A view from a pharmacist patient.
作者信息
Smiley Tom
机构信息
Pharmavision Health Consulting Inc., Paris, Ontario.
出版信息
Can Pharm J (Ott). 2013 Mar;146(2):97-100. doi: 10.1177/1715163513481319.
Abstract
摘要
相似文献
1
Putting cardiovascular risk into perspective: A view from a pharmacist patient.正确看待心血管疾病风险：一位药剂师患者的视角
Can Pharm J (Ott). 2013 Mar;146(2):97-100. doi: 10.1177/1715163513481319.
2
A patient perspective of pharmacist prescribing: 'crossing the specialisms-crossing the illnesses'.患者眼中的药剂师处方：“跨越专业界限——跨越疾病”。
Health Expect. 2015 Feb;18(1):58-68. doi: 10.1111/hex.12008. Epub 2012 Oct 15.
3
Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).药剂师管理的高血压项目对卫生系统成本的影响：对心血管风险干预的药剂师研究-高血压（SCRIP-HTN）的评估。
Pharmacotherapy. 2012 Jun;32(6):527-37. doi: 10.1002/j.1875-9114.2012.01097.x. Epub 2012 May 2.
4
Evaluation of a transitional care pharmacist intervention in a high-risk cardiovascular patient population.对高危心血管疾病患者群体进行过渡性护理药剂师干预的评估。
Am J Health Syst Pharm. 2018 Sep 1;75(17 Supplement 3):S63-S71. doi: 10.2146/ajhp170099. Epub 2018 Jul 5.
5
Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk.药剂师心血管风险干预研究（SCRIP）：一项关于社区药剂师干预计划对血清胆固醇风险影响的随机试验设计。
Ann Pharmacother. 1999 Sep;33(9):910-9. doi: 10.1345/aph.18380.
6
Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials.药剂师护理对心血管疾病危险因素管理的影响：一项随机试验的系统评价和荟萃分析
Arch Intern Med. 2011 Sep 12;171(16):1441-53. doi: 10.1001/archinternmed.2011.399.
7
A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist-Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (REACH).一项社区药剂师主导的降低心血管风险干预措施的成本分析和成本效益分析：艾伯塔省血管风险降低社区药房项目（REACH）。
Value Health. 2019 Oct;22(10):1128-1136. doi: 10.1016/j.jval.2019.05.012. Epub 2019 Aug 17.
8
Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: a planned subgroup analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).强化药师照护对糖尿病患者胆固醇管理的更大影响：药师心血管风险干预研究（SCRIP）的一项计划亚组分析
Pharmacotherapy. 2004 Mar;24(3):389-94. doi: 10.1592/phco.24.4.389.33169.
9
Putting it into perspective: multimarker panels for cardiovascular disease risk assessment.从多个角度看问题：用于心血管疾病风险评估的多标志物检测。
Biomark Med. 2013 Apr;7(2):317-27. doi: 10.2217/bmm.13.15.
10
Exploring patient expectations for pharmacist-provided literacy-sensitive communication.探讨患者对药剂师提供的具有文化敏感性的沟通的期望。
Res Social Adm Pharm. 2013 Sep-Oct;9(5):626-32. doi: 10.1016/j.sapharm.2012.05.012. Epub 2012 Jul 25.
本文引用的文献
1
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.2009年加拿大心血管学会/加拿大成人血脂异常诊断与治疗及心血管疾病预防指南——2009年推荐意见
Can J Cardiol. 2009 Oct;25(10):567-79. doi: 10.1016/s0828-282x(09)70715-9.
2
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.瑞舒伐他汀预防C反应蛋白升高的男性和女性发生血管事件。
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
3
C-reactive protein and atherogenesis: from fatty streak to clinical event.C反应蛋白与动脉粥样硬化形成：从脂纹到临床事件
Atherosclerosis. 2007 Dec;195(2):e10-8. doi: 10.1016/j.atherosclerosis.2007.04.053. Epub 2007 Jul 31.
4
Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus).
Am J Med. 2004 Jan 15;116(2):130-3. doi: 10.1016/j.amjmed.2003.09.024.
5
Prevalence of conventional risk factors in patients with coronary heart disease.冠心病患者中传统危险因素的患病率。
JAMA. 2003 Aug 20;290(7):898-904. doi: 10.1001/jama.290.7.898.
6
A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).
Arch Intern Med. 2002 May 27;162(10):1149-55. doi: 10.1001/archinte.162.10.1149.
7
Lipids, risk factors and ischaemic heart disease.
Atherosclerosis. 1996 Jul;124 Suppl:S1-9. doi: 10.1016/0021-9150(96)05851-0.
Zotero 插件